The drug, gedatolisib, in combination with Pfizer's Ibrance and AstraZeneca's endocrine therapy Faslodex, reduced the risk of ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...

The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...

The biopharmaceutical company AstraZeneca announced it will $50 billion into the United States, with plans to open several ...

AstraZeneca said it would invest $50 billion in U.S. production by 2030. At the core is a manufacturing plant to go somewhere in Virginia.

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030.

The biopharmaceutical company said the investment includes plans for a new manufacturing center focused on chronic diseases.